Indian Price Controls To Cap Cost Of Insulin Drugs
This article was originally published in PharmAsia News
India's drug pricing authority plans to cap the price of insulin drugs to curb what it considers transfer pricing abuse. The National Pharmaceutical Pricing Authority relies on production costs used by domestic drug makers to set a retail price, but has no access to similar information from firms owned or operated outside the country. Its ceiling on the price of both injectable and cartridge insulin covers imported and domestic brands, but about 90 percent of the market is dominated by imports. (Click here for more
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?